AI & Jobs Foghorn Cuts 40% After a Lilly Trial Stalls. AI Isn't the Reason
Foghorn Therapeutics said on October 1 it is cutting about 40% of its workforce, leaving roughly 65 full-time employees, after it and Eli Lilly decided not to advance the FHD-909 trial. The 8-K names no AI or automation link.